Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292655 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 8
- Study locations
NCT01292655: Completed Phase 1 study of Cancer, sponsored by Bristol-Myers Squibb.
NCT01292655 is a Phase 1 study of Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 94 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01292655, a Phase 1 study of Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.
Conditions Studied
Interventions
- DRUG BMS-906024
Study Locations (8)
California
- Anthony El-Khoueiry, Md - Los Angeles
Georgia
- Winship Cancer Institute. - Atlanta
Michigan
- Wayne State University - Detroit
Mississippi
- University Of Mississippi Medical Center - Jackson
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Texas
- The Methodist Hospital Research Institute - Houston
Victoria
- Local Institution - Parkville
Ontario
- Local Institution - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2011-03-03 |
| Est. Completion | 2017-06-22 |
| Phase | Phase 1 |
What the finished NCT01292655 record still lists
NCT01292655 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which BMS-906024 is the first listed.
NCT01292655 lists 8 locations in 8 states (California, Georgia, Michigan).
Frequently Asked Questions
What is clinical trial NCT01292655 about?
NCT01292655 is a clinical study titled "Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors". The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.
What is the current status of trial NCT01292655?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2011-03-03. Estimated completion is 2017-06-22.
What conditions does trial NCT01292655 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01292655?
The interventions under investigation include: BMS-906024 (DRUG).
Who is sponsoring clinical trial NCT01292655?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01292655 being conducted?
This trial has 8 study locations across California, Georgia, Michigan, Mississippi, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01292655's enrollment target sits among peer trials
94 333rd of 615 higher than 283 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI